Auditory and vestibular dysfunction in patients with Parkinson’s disease

Hussein, M. M.; Koura, Rabab Ahmed

doi:10.4103/ejo.ejo_18_18

Cited by 5 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with previous studies (Al Jaja et al, 2020;De Keyser et al, 2019;Di Mauro et al, 2017;Lopes et al, 2018;Richardson & Sussman, 2019), no significant differences were found between patients with PD and HCs regarding auditory thresholds, irrespective of medication condition. In contrast, a number of studies have reported significantly increased auditory thresholds in patients with PD, primarily in the high-frequency range (Al Zarea et al, 2016;Folmer et al, 2017;Hussein & Koura, 2019;Pisani et al, 2015;Scarpa et al, 2020;Shalash et al, 2017;Shetty et al, 2019;Vitale et al, 2016Vitale et al, , 2012Yýlmaz et al, 2009). Different study results may be due to the statistical method chosen to analyze audiometric data measured at multiple frequencies and for left and right ears.…”

Section: Discussionmentioning

confidence: 96%

“…For example, a positive correlation has been reported between measures of disease progression on the one hand and auditory thresholds (Al Zarea et al, 2016;Pisani et al, 2015;Vitale et al, 2016Vitale et al, , 2012 and OAEs on the other hand (Di Mauro et al, 2017). In contrast, other studies did not find significant correlations between disease progression and auditory thresholds (Hussein & Koura, 2019) or OAE signal amplitudes (Pisani et al, 2015). However, these correlations should be interpreted carefully, as they do not account for potentially confounding variables, such as age.…”

mentioning

confidence: 97%

“…On the one hand, a number of studies did not find significant differences between patients with PD and age-matched healthy controls (HCs) regarding auditory thresholds (Al Jaja et al, 2020;De Keyser et al, 2019;Di Mauro et al, 2017;Lopes et al, 2018;Richardson & Sussman, 2019). On the other hand, studies have reported significantly higher auditory thresholds or a higher prevalence of hearing impairment in patients with PD compared to age-matched HCs, primarily in the high-frequency range (Al Zarea et al, 2016;Folmer et al, 2017;Hussein & Koura, 2019;Pisani et al, 2015;Scarpa et al, 2020;Shalash et al, 2017;Shetty et al, 2019;Vitale et al, 2016Vitale et al, , 2012Yýlmaz et al, 2009). The most generally accepted theory suggests that increased highfrequency auditory thresholds in PD represent the combined effect of age-related processes (i.e., presbycusis) and the pathophysiological changes intrinsic to PD (Vitale et al, 2012).…”

mentioning

confidence: 99%

See 2 more Smart Citations

The Effect of Parkinson's Disease on Otoacoustic Emissions and Efferent Suppression of Transient Evoked Otoacoustic Emissions

Groote

Bockstael

Botteldooren

et al. 2021

J Speech Lang Hear Res

View full text Add to dashboard Cite

Purpose Several studies have demonstrated increased auditory thresholds in patients with Parkinson's disease (PD) based on subjective tonal audiometry. However, the pathophysiological mechanisms underlying auditory dysfunction in PD remain elusive. The primary aim of this study was to investigate cochlear and olivocochlear function in PD using objective measurements and to assess the effect of dopaminergic medication on auditory function. Method Eighteen patients with PD and 18 gender- and age-matched healthy controls (HCs) were included. Patients with PD participated in medication on and off conditions. Linear mixed models were used to determine the effect of PD on tonal audiometry, transient evoked and distortion product otoacoustic emissions (OAEs), and efferent suppression (ES). Results Tonal audiometry revealed normal auditory thresholds in patients with PD for their age across all frequencies. OAE signal amplitudes demonstrated a significant interaction effect between group (PD vs. HC) and frequency, indicating decreased OAEs at low frequencies and increased OAEs at high frequencies in patients with PD. No significant differences were found between patients with PD and HCs regarding ES. In addition, no significant effect of medication status was found on auditory measurements in patients with PD. Conclusions Altered OAEs support the hypothesis of cochlear alterations in PD. No evidence was found for the involvement of the medial olivocochlear system. Altogether, OAEs may provide an objective early indicator of auditory alterations in PD and should complement subjective tonal audiometry when assessing and monitoring auditory function in PD.

show abstract

Section: Discussionmentioning

confidence: 96%

mentioning

confidence: 97%

mentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Parkinson's Disease on Otoacoustic Emissions and Efferent Suppression of Transient Evoked Otoacoustic Emissions

Groote

Bockstael

Botteldooren

et al. 2021

J Speech Lang Hear Res

View full text Add to dashboard Cite

show abstract

“…Nevertheless, the results focusing on the latencies of VEMPs in PD were divided. Many studies revealed that patients with PD showed significantly delayed cVEMP P13 and N23 latencies compared with controls [ 16 , 27 ]. There was still evidence that was consistent with previous observations suggesting that the cVEMP P13 latency was significantly increased in patients with PD, whereas no significant differences in N23 latency was found [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

“…VEMP abnormalities have been widely reported in patients with PD, and they comprise absent, delayed, or low-amplitude VEMP responses [ 15 , 16 ]. Contrarily, there have also been studies indicating the opposite or no significant difference in VEMP findings in patients with PD compared with controls [ 7 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

Assessment of Vestibular-Evoked Myogenic Potentials in Parkinson’s Disease: A Systematic Review and Meta-Analysis

2022

View full text Add to dashboard Cite

(1) Background: The brainstem plays an essential role in the early stage of Parkinson’s disease (PD), but it is not widely tested in clinical examinations of PD. Vestibular-evoked myogenic potentials (VEMPs) are recognized as fundamental tools in the assessment of brainstem function. The aim of our meta-analysis was to assess the abnormal findings of VEMPs in patients with PD. (2) Methods: Up to 14 February 2022, PubMed, Embase, and Web of Science were searched to evaluate VEMPs in patients with PD in comparison with respective controls. The study protocol was registered at PROSPERO (CRD42022311103). (3) Results: A total of 15 studies were finally included in our meta-analysis. The absence rates of VEMPs in patients with PD were significantly higher than those of control groups (cVEMP: OR = 6.77; oVEMP: OR = 13.9; mVEMP: OR = 7.52). A delayed P13 latency, a decreased peak-to-peak amplitude, and an increased AAR of cVEMP, and a delayed oVEMP P15 latency were also found in patients with PD. (4) Conclusions: Our meta-analysis indicates abnormal VEMP findings in patients with PD, revealing the dysfunction of the brainstem in PD. VEMP tests, especially cVEMP tests, could be a helpful method for the early detection of PD.

show abstract